Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Stankoff

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
Neurology|January 31, 2016
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational studyLaetitia Barbin, Chloe Rousseau, Natacha Jousset, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 26, 2022
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod WithdrawalFabien Rollot, Justine Couturier, Romain Casey, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 11, 2025
Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple SclerosisMarie Mainguy, Romain Casey, Sandra Vukusic, et al.
Blood Advances|June 12, 2026
Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathyJean-Roch Le Henaff, Loïc Le Guennec, Pauline Schiro, et al.
European Journal of Neurology|March 2, 2021
Untreated patients with multiple sclerosis: A study of French expert centersXavier Moisset, Audrey-Anne Fouchard, Bruno Pereira, et al.
Neurology|September 25, 2024
Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life StudyMarion Hay, Fabien Rollot, Romain Casey, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 14, 2022
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring systemCamille Sabathé, Romain Casey, Sandra Vukusic, et al.
JAMA Neurology|September 4, 2019
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in FranceSandra Vukusic, Fabien Rollot, Romain Casey, et al.
The Lancet. Neurology|August 21, 2021
Myelin-oligodendrocyte glycoprotein antibody-associated diseaseRomain Marignier, Yael Hacohen, Alvaro Cobo-Calvo, et al.
Neurology|July 14, 2019
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosisDavid-Axel Laplaud, Romain Casey, Laetitia Barbin, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
Neurology|January 31, 2016
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational studyLaetitia Barbin, Chloe Rousseau, Natacha Jousset, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 26, 2022
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod WithdrawalFabien Rollot, Justine Couturier, Romain Casey, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 11, 2025
Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple SclerosisMarie Mainguy, Romain Casey, Sandra Vukusic, et al.
Blood Advances|June 12, 2026
Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathyJean-Roch Le Henaff, Loïc Le Guennec, Pauline Schiro, et al.
European Journal of Neurology|March 2, 2021
Untreated patients with multiple sclerosis: A study of French expert centersXavier Moisset, Audrey-Anne Fouchard, Bruno Pereira, et al.
Neurology|September 25, 2024
Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life StudyMarion Hay, Fabien Rollot, Romain Casey, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 14, 2022
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring systemCamille Sabathé, Romain Casey, Sandra Vukusic, et al.
JAMA Neurology|September 4, 2019
Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in FranceSandra Vukusic, Fabien Rollot, Romain Casey, et al.
The Lancet. Neurology|August 21, 2021
Myelin-oligodendrocyte glycoprotein antibody-associated diseaseRomain Marignier, Yael Hacohen, Alvaro Cobo-Calvo, et al.
Neurology|July 14, 2019
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosisDavid-Axel Laplaud, Romain Casey, Laetitia Barbin, et al.
Pageof 16